Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia

Blood (2024) 144 (Supplement 1): 2194.

https://doi.org/10.1182/blood-2024-200152

Published: 2024

Journal Articles

Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Julie Kanter, MD, John F. Tisdale, MD, Markus Y Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Ren Chen, Meghan E. Gallagher, MSc, Yuchen Ding, PhD, Sunita Goyal, MD, Clark Paramore, MPH, Alexis A. Thompson, MD, Mark C. Walters, MD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-136193

Published: 2020

Journal Articles

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

Farrukh Shah, MDMBBS,FRCPath, Paul Telfer, DM, FRCP, Mark Velangi, Shivan Pancham, Robert Wynn, Sally Pollard, Elizabeth Chalmers, Jonathan Kell, MD, Joe Hickey, PhD, Clark Paramore, MPH, Minesh Jobanputra, MD, Kate Ryan, MD

Blood (2019) 134 (Supplement_1): 3550.

https://doi.org/10.1182/blood-2019-129930

Published: 2019

Journal Articles

Characterizing a Population with Severe Manifestations of Sickle Cell Disease Using U.S. Real-World Evidence

Clark Paramore, MPH, Amanda Kong, MPH, Sachiyo Minegishi, Weiliang Shi, PhD

Blood (2018) 132 (Supplement 1): 4811.

https://doi.org/10.1182/blood-2018-99-118874

Published: 2018

Journal Articles

Treatment Patterns and Costs of Transfusion and Chelation in Commercially-Insured and Medicaid Patients with Transfusion-Dependent β-Thalassemia

Clark Paramore, MSPH, Anna Vlahiotis, PhD, Meghan Moynihan, PhD, Katherine Cappell, PhD, Alejandra Ramirez-Santiago, MD

Blood (2017) 130 (Supplement 1): 5635.

https://doi.org/10.1182/blood.V130.Suppl_1.5635.5635

Published: 2017

NARROW

Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia

Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

Characterizing a Population with Severe Manifestations of Sickle Cell Disease Using U.S. Real-World Evidence

Treatment Patterns and Costs of Transfusion and Chelation in Commercially-Insured and Medicaid Patients with Transfusion-Dependent β-Thalassemia

Email alerts

ASH Publications

American Society of Hematology

Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia

Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

Characterizing a Population with Severe Manifestations of Sickle Cell Disease Using U.S. Real-World Evidence

Treatment Patterns and Costs of Transfusion and Chelation in Commercially-Insured and Medicaid Patients with Transfusion-Dependent β-Thalassemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only